a positive trendgold
Notably, when considering intrinsic subtypes, as shown in Figure 6 , luminal A patients (typically low-grade ER + tumors) had the most pronounced CLDN8-related benefit, whereas the luminal B subgroup (often more proliferative or HER2 + ER + tumors; Figure 6 F) showed a positive trend that did not reach strong significance.